@article{12890dc1111948a9b6966f719fcb5ddb,
title = "The clinical and neuropathological features of sporadic (Late-onset) and genetic forms of alzheimer{\textquoteright}s disease",
abstract = "The purpose of this review is to compare and highlight the clinical and pathological aspects of genetic versus acquired Alzheimer{\textquoteright}s disease: Down syndrome-associated Alzheimer{\textquoteright}s disease in (DSAD) and Autosomal Dominant Alzheimer{\textquoteright}s disease (ADAD) are compared with the late-onset form of the disease (LOAD). DSAD and ADAD present in a younger population and are more likely to manifest with non-amnestic (such as dysexecutive function features) in the prodromal phase or neurological features (such as seizures and paralysis) especially in ADAD. The very large variety of mutations associated with ADAD explains the wider range of phenotypes. In the LOAD, age-associated comorbidities explain many of the phenotypic differences.",
keywords = "Autosomal dominant Alzheimer {\textquoteright}s disease, Clinical features, Down syndrome, Late-onset Alzheimer{\textquoteright}s disease, Neuropathology",
author = "Tanzil Rujeedawa and F{\'e}lez, {Eva Carrillo} and Clare, {Isabel C.H.} and Juan Fortea and Andre Strydom and Rebillat, {Anne Sophie} and Antonia Coppus and Johannes Levin and Zaman, {Shahid H.}",
note = "Funding Information: Funding: This review was funded by Fondation J{\'e}r{\^o}me Lejeune for the HORIZON 21 consortium. Other funds for I.C.H.C.: NIHR ARC East of England at Cambridgeshire & Peterborough NHS Foundation Trust; J.F.: the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI14/01126, PI17/01019 and PI20/01473) and the CIBERNED program (Program 1, Alzheimer Disease and SIGNAL study, www.signalstudy.es, accessed on 1 July 2021), partly jointly funded by Fondo Europeo de Desarrollo Regional, Uni{\'o}n Europea, Una manera de hacer Europa. The work was also supported by the National Institutes of Health (NIA grants 1R01AG056850-01A1; R21AG056974 and R01AG061566), Fundaci{\'o} La Marat{\'o} de TV3 (20141210), grants from Fundaci{\'o} V{\'i}ctor Gr{\'i}fols i Lucas, and by the Generalitat de Catalunya (SLT006/17/00119); A.S.:the MRC (MR/S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The LeJeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21-848077). A.-S.R.: Fondation J{\'e}r{\^o}me Lejeune for the TRIAL 21 study and the HORIZON 21 consortium; S.H.Z.: Fondation J{\'e}r{\^o}me Lejeune for the HORIZON 21 consortium. Funding Information: This review was funded by Fondation J?r?me Lejeune for the HORIZON 21 consortium. Other funds for I.C.H.C.: NIHR ARC East of England at Cambridgeshire & Peterborough NHS Foundation Trust; J.F.: the Fondo de Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI14/01126, PI17/01019 and PI20/01473) and the CIBERNED program (Program 1, Alzheimer Disease and SIGNAL study, www.signalstudy.es, accessed on 1 July 2021), partly jointly funded by Fondo Europeo de Desarrollo Regional, Uni?n Europea, Una manera de hacer Europa. The work was also supported by the National Institutes of Health (NIA grants 1R01AG056850-01A1; R21AG056974 and R01AG061566), Fundaci? La Marat? de TV3 (20141210), grants from Fundaci? V?ctor Gr?fols i Lucas, and by the Generalitat de Catalunya (SLT006/17/00119); A.S.:the MRC (MR/S011277/1; MR/S005145/1; MR/R024901/1), Lumind IDSC, The LeJeune Foundation and the European Commission (H2020 SC1 Gene overdosage and comorbidities during the early lifetime in Down Syndrome GO-DS21-848077). A.-S.R.: Fondation J?r?me Lejeune for the TRIAL 21 study and the HORIZON 21 consortium; S.H.Z.: Fondation J?r?me Lejeune for the HORIZON 21 consortium. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = oct,
day = "1",
doi = "10.3390/jcm10194582",
language = "English",
volume = "10",
journal = "Journal of Clinical Medicine",
issn = "2077-0383",
publisher = "MDPI",
number = "19",
}